to overcome many of the obstacles in studying rare enriched variants that contribute to the risk of complex diseases. 11 We designed a targeted gene sequencing protocol to screen the coding and splicing areas of genes of interest within angiogenic and vascular pathways and other putative candidate genes in a sizeable cohort of preeclampsia cases and controls from Finland. Here, we explore the potential causal role of variation in candidate genes in preeclampsia.
Methods

Diagnostic Criteria and Patient Cohorts
The study design is outlined in Figure. At stage 1, we studied 500 nonobese (body mass index <30 kg/m 2 ) women with preeclamptic pregnancies and 190 nonpreeclamptic controls that were matched geographically, in age, and in body mass index from the FINNPEC cohort (Finnish Genetics of Preeclampsia Consortium), a casecontrol cohort recruited from the 5 Finnish University Hospitals. 12 Nulliparous or multiparous women with a singleton pregnancy were eligible for the study. Preeclampsia was defined as hypertension and proteinuria occurring after 20 week's gestation. Hypertension was defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg after 20 weeks of gestation. Proteinuria was defined as the urinary excretion of ≥0.3 g protein in a 24-hour specimen, or 0.3 g/L, or 2 ≥1+ readings on dipstick in a random urine determination with no evidence of urinary tract infection. All diagnoses were independently verified by a research nurse and a physician. Seven preeclamptics and 1 control were excluded because of a failure in genotyping, and further 9 cases were excluded because of non-Finnish ethnicity and ovum donation pregnancy. The characteristics of the study participants are presented in Table S1 in the online-only Data Supplement. All women provided a written informed consent, and the FINNPEC study protocol was approved by the coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa.
At stage 2, we included in the analyses whole-exome sequencing from an additional 122 women with a history of preeclampsia and 1905 parous women with no such history from the national FINRISK study cohort (FINRISK license 8/2016). 13 For identifying preeclampsia and eclampsia cases in the FINRISK study cohort, we used fol- All polymorphic sites in the stage 1-targeted sequencing were queried from the population cohort exomes. All of the National FINRISK study methodology and ethical approvals are available online: https://www.thl.fi/en/web/thlfi-en/research-and-expertwork/ population-studies/the-national-finrisk-study.
Preparation of Genomic DNA
Genomic DNA was extracted from whole blood using the NucleoSpin Blood XL DNA extraction kit (Macherey-Nagel GmbH & Co.) or the Chemagic Magnetic Separation Module I-machine (Chemagen) and subsequently stored at −20°C.
Targeted Sequencing and Capture Enrichment
Genes implicated in human biomarker studies were chosen as targeted candidate genes as were their signaling partners and proteases that alter their function and levels. Specific single nucleotide polymorphisms (SNPs) and any neighboring or associated gene that have been enriched in preeclamptic women based on metaanalysis, genome-wide association studies, or functional studies were included. This list of existing candidate genes was based on review of literature in January 2013, and it included genes involved in angiogenesis, such as FLT1, and pregnancy, such as pregnancyzone protein, among other relevant functional pathways. The studied genes are listed in Table S2 .
Libraries from genomic DNA were prepared in-house (Washington University School of Medicine).
14 Enzymes were purchased from Enzymatics (Beverly, MA). Briefly, the ends of sheared genomic DNA fragments were repaired by treatment with T4 DNA polymerase and T4 DNA polynucleotide kinase, which phosphorylates the 5′ hydroxyl group. An adenosine was then added to the 3′ position at each end of the DNA fragment with Taq Polymerase. Illumina adapters with an overhanging T were ligated onto the DNA fragment followed by bead-based size selection procedure to remove adapter dimers and fragments below the desired size. A unique index sequence was added by polymerase chain reaction by targeting the 2 ligated universal adapters on each fragment end.
Sequence capture by hybridization was performed according to the manufacturer's recommendations with modifications (Roche SeqCap Hybridization and Wash Kit No. 05634261001). We used longer blocking oligos containing an additional 7 bp inosine segment for promiscuous pairing with different index sequences. After hybridization, captured DNA was washed and eluted according to the manufacturer's instructions. 
Sequencing and Analysis
Sequencing was performed on an Illumina HiSeq 2000 at the Washington University Genome Technology Access Center using 2×101 bp, 2×135 bp, and 2×150 bp reads. We aligned sequencing to GRCh37 using bwa aln (v0.6.1-r104) and genotyped the samples using the Genome Analysis ToolKit (v2.5.2-gf57256b) Unified Genotyper.
15-17
Statistical Analyses
Quality control before meta-analysis included removal of singleton and monomorphic variants, removal of sites with >10% missing data in the targeted sequencing, or a significant departure from HardyWeinberg equilibrium in controls (P<0.001). The combined data set was analyzed using Fisher exact test that served as our primary association test. The analysis was divided into 2 classes: low frequency and rare variants (minor allele frequency [MAF] <10%) or common variants (MAF>10%). After quality control, 622 variants (443 variants with MAF<10% and 179 variants with MAF>10%) were advanced to the combined primary analysis. Of these, 201 were in putatively functional categories (missense, nonsense, or splice region variants) and 421 were in likely benign categories (synonymous, intronic, and intergenic).
The 2 SNPs with strongest associations were further compared with 672 predefined epidemiological diagnoses derived from national healthcare registries using imputed genotypes of 11 257 FINRISK women. Genotypes were imputed using a combined panel of Finnish whole-genome sequences and 1000 Genomes phase I reference with a high-imputation confidence (info metric >0.97).
18,19 Associations were calculated using logistic regression (SNPTEST v2.5.2, EM algorithm) and then further confirmed with Fisher exact test given the rarity of variants and several diagnoses. Because of the explorative nature of this part of the analysis, no multiple testing corrections to estimates were performed. Heart failure was identified using codes I50, 4289X, and 42700 in Finnish ICD-10, ICD-9, and ICD-8, respectively.
Data were analyzed using PlinkSeq, Plink, 20 and R. Kaviar, 21 and VEP Build 37 was used in additional annotations. 22 Loss of function (LoF) analyses were conducted for each gene with associating variants in silico by the LoF tool (https://github.com/ensembl-variation/ VEP_plugins/blob/master/LoFtool.pm). The following annotations were calculated: LoF score <0.2 is probably damaging, LoF score 0.2 to 0.7 is possibly damaging, LoF score <0.7 is benign. In addition to appropriate statistical probability tests, odds ratios (OR) with 95% confidence intervals were calculated for all variants.
Results
Results of the association analyses are listed in Table. For these studies, genotypes from stage 1 (FINNPEC) were combined with a population cohort in stage 2 (FINRISK) for joint analysis. Forty-one variants demonstrated nominal association (P<0.05; 34 uncommon and 7 common). The tail of the P value distribution of benign variants was as expected (0 results with P<0.001; expected ≤1 and 2 results with P<0.01; expected ≤4.2), suggesting that the overall study design and quality control were successful. Among the 201 putatively functional variants, one had P<0.001 (α=0.05) compared with the 0 of 421 observed among benign variants. The lack of inflated P values points out that confounders, such as stratification, are not causing false positives.
Focusing on 146 putatively functional (missense or truncating) rare and low-frequency variants, we observed an excess (observed 13, expected 7.3) of nominally associated variants (P<0.05). The strongest associations observed were in FLT1, with 2 missense variants associated to preeclampsia: NM_002019. 4 
Discussion
We discovered low-frequency protective genetic variants in FLT1 that contributed to lower preeclampsia risk. We also found associating genetic variants in known candidate genes using a targeted sequencing approach. These FLT1 variants may also be associated with lower risk of heart failure.
FLT1 codes for VEGFR1 (vascular endothelial growth factor receptor 1). It consists of 7 immunoglobulin-like domains in an extracellular ligand-binding region, a transmembrane segment, and a cytoplasmic region containing a tyrosine kinase domain. 23 VEGFR1 is essential for survival by negatively regulating the levels of endogenous vascular endothelial growth factor. Internalization and signaling of functional VEGFRs will enhance angiogenic growth of blood vessels. 24 Sustaining angiogenesis is necessary for circulation, and antiangiogenic treatment causes cardiovascular morbidity. 25 There are multiple isoforms of VEGFR1 of which the soluble forms have been implicated in preeclampsia. The soluble forms of VEGFR1 only contain the extracellular parts of the protein encoded by the first 13 of 30 exons. In preeclampsia, an excess of VEGFR1 of placental origin has been recorded. 26 Furthermore, after healthy endothelium is restored, elevated levels of soluble VEGFR1 are observed in women with a history of preeclampsia. 27 Increased levels of sFLT1/sVEGFR1 have also been indicated in peripartum cardiomyopathy where high levels of sFLT1 correlate with the symptoms' severity. 28 Similarly, heart failure after myocardial infarction independent of pregnancy is reflected in extreme levels of sFLT1. 29 Rhee et al report extreme sFLT1 levels in at least the 95th percentile in a cases of heart failure during pregnancy. 30 Although further research is required to assess the effect of underlying risk factor profile in preeclamptic women's increased risk of heart failure in later life, it was recently shown in a metaanalysis of results from 7 studies that 3.6-fold increase in risk of heart failure is associated with preeclampsia, particularly during the time period of 1 to 10 years after preeclampsia. 31 Preeclampsia increases the risk of peripartum cardiomyopathy, and it has been suggested that sFLT1 may be toxic to the heart. Also the driver of the cardiac dysfunction in susceptible preeclamptics is likely mediated by antiangiogenic factors. 32 Our results indicate that FLT1 variants that protect from preeclampsia may also protect from heart failure, thereby adding to the growing body of evidence that imbalance of angiogenic factors may be the link between preeclampsia and cardiovascular morbidity in later life in susceptible individuals. Novel therapeutic options for these individuals may include blocking sFLT1 production or neutralizing antibodies against angiogenic proteins.
33,34
From the observed associating variants in FLT1, rs141440705 causing R54S is more likely of functional importance. This is because it results in a polar change (pos→neutral) within the immunoglobulin-like domain 1, a functional part of the protein. 35 Rs141440705 is located in the last nucleotide of an exon. Therefore, the variant may affect splicing, as well as the coded amino acid sequence.
Epidemiological studies with many of the protective associations from severe cardiovascular diseases are strongest for R54S, supporting the suggestion of functional significance. The other variant resulting in the amino acid substitution E982A is not included in the sFLT1 or the VEGFR1 isoform 2, which is the dominant isoform in the placenta. Even so, because VEGFR1 isoform 1 (canonical sequence) is expressed in vascular endothelium, E982A might have an important role in pregnancy in mediating decidual blood flow and in remodeling the spiral arteries.
We also found support for the role of several other candidate genes in preeclampsia. Corin has been previously indicated in preeclampsia with population-specific variants. 36 Stepanian et al 36 report similar ORs of ≈2.5 at 2 intronic SNPs, rs2271036 and rs2271037 to our finding at rs61759670 and rs61760500. Rs13406336 and rs4556933 in activin A receptor type 1C have been previously listed as a candidate SNPs although no significant association to preeclampsia was established in a Norwegian population. 37 Interestingly, rs7830 features in numerous studies that pinpoint the association of nitric oxide synthase 3 to a spectrum of multifactorial diseases. Most relevantly, a haplotype including rs7830 was found to protect women from pregnancy hypertension and preeclampsia. 38 Rs1554286 in interleukin 10 has been shown to belong to an intronic haplotype, which strongly predisposes women of Bahraini Arab population to idiopathic recurrent miscarriages. 39 Our findings support the hypothesis that common immunologic pathogenesis may be shared between recurrent miscarriages and preeclampsia.
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Perspectives
To our knowledge, this study provides the first evidence that maternal FLT1 sequence variants associate with lower preeclampsia susceptibility. Further research is required to pinpoint the mechanism of protection from preeclampsia and heart failure and the effect of FLT1 variants on gene transcription. Genetic associations may open new avenues of drug development once the functional consequences of our findings are further deciphered. Genetic protection from preeclampsia because of FLT1 variants may also protect these women from heart failure in later life. 
